Skip to main content
Figure 1 | BMC Musculoskeletal Disorders

Figure 1

From: Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment

Figure 1

Telomeric KIR haplotype profiles in MTX good responder and poor responder RA patient groups. Grey box: gene presence; white box: gene absence. Estimation of KIR gene frequency based on haplotype distributions shown for KIR3DL1 – 81.5% and 78.7%, for KIR3DS1 18.6% and 21.5%, for KIR2DS5 15.9% and 18.1%, for KIR2DS1 22.4% and 26.0%, for KIR2DS4f 16.4% and 20.3%, for KIR2DS4d 63.3% and 56.3%, in good responder and poor responder groups, respectively.

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us